2023年美国临床肿瘤学会(ASCO)年会将于美国中部夏令时间(CDT)6月2日至6月6日在芝加哥以线上结合线下的形式举行。肺癌领域将有一系列重磅研究公布,其中最引人瞩目的当属创新的物理疗法——肿瘤电场治疗(Tumor Treating Fields,TTFields)在...
ASCO 2023 - American Society of Clinical Oncology (ASCO) Annual Meeting Date: June 2-6, 2023 Venue: McCormick Place • Chicago, Illinois, United States + Online 2023年美国临床肿瘤学会 (ASCO) 年会将于2023年6月2日至...
will present new data evaluating the use and potential of its methylation-based multi-cancer early detection (MCED) platform at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2-6. Presentations include interim...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present nine abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Data from multiple studies of inv...
(“BlissBio”) a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced today BB-1701 Phase 1 study data will be presented at the American Society of Clinical Oncology (2023 ASCO Annual Meeting), to be held from June 2 to 6, 2023...
Date/Time:June 5, 2023, 1:15 - 4:15 p.m. CT Presenter:Tab Cooney, MD, Day One Biopharmaceuticals Day One will also have a Medical Information booth at the 2023 ASCO Annual Meeting at booth number 27155...
Home 2023 ASCO Annual Meeting Roche and Genentech at2023 ASCO Annual MeetingJune 02 - June 06 Chicago, USA am.asco.org Medical Materials Agenda Scientific Area Disease Area Date Type Personalized Healthcare Clear Jun 5 / Roche and Genentech SUNMO: A Phase III trial evaluating the...
The annual meeting of the American Society of Medical Oncology (ASCO) was held as usual in Chicago, while the meeting focused on gastrointestinal tumors, A
DUBLIN, April 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present nine abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Presentations include...
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024 Published Jun 4, 2024 7:00am EDT CAR031 study at 9.03-mo median follow up achie...